These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
537 related articles for article (PubMed ID: 2013930)
21. A field trial of combined measles-mumps-rubella vaccine. Satisfactory immunization with 188 children in Chile. Borgoño JM; Greiber R; Solari G; Concha F; Carrillo B; Hilleman MR Clin Pediatr (Phila); 1973 Mar; 12(3):170-2. PubMed ID: 4701464 [No Abstract] [Full Text] [Related]
22. [Immunity to measles, mumps and rubella in children vaccinated with triple viral vaccine]. Pisón Garcés FJ; Galbe Sánchez-Ventura J; Arcauz Eguren P; Aguirre y Dabán C; Mengual Gil J; Larrad Mur L Aten Primaria; 1995 Mar; 15(4):235-7. PubMed ID: 7703334 [TBL] [Abstract][Full Text] [Related]
23. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps]. Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598 [TBL] [Abstract][Full Text] [Related]
24. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus. Molyneaux PJ; Mok JY; Burns SM; Yap PL J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316 [TBL] [Abstract][Full Text] [Related]
25. Antibody response following measles-mumps-rubella vaccine under conditions of customary use. Brunell PA; Weigle K; Murphy MD; Shehab Z; Cobb E JAMA; 1983 Sep; 250(11):1409-12. PubMed ID: 6887461 [TBL] [Abstract][Full Text] [Related]
26. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population]. Janaszek-Seydlitz W; Bucholc B; Wysokińska T; Górska P; Gniadek G Przegl Epidemiol; 2003; 57(2):281-8. PubMed ID: 12910596 [TBL] [Abstract][Full Text] [Related]
27. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L; Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779 [TBL] [Abstract][Full Text] [Related]
28. Prevalence of IgG-antibodies to mumps and measles virus in non-vaccinated children. Glikmann G; Petersen I; Mordhorst CH Dan Med Bull; 1988 Apr; 35(2):185-7. PubMed ID: 3359817 [TBL] [Abstract][Full Text] [Related]
29. Two doses of MMR vaccine--sufficient to eradicate measles, mumps and rubella? Fahlgren K Scand J Soc Med; 1988; 16(3):129-35. PubMed ID: 3057621 [TBL] [Abstract][Full Text] [Related]
30. A search for persistent measles, mumps, and rubella vaccine virus in children with human immunodeficiency virus type 1 infection. Frenkel LM; Nielsen K; Garakian A; Cherry JD Arch Pediatr Adolesc Med; 1994 Jan; 148(1):57-60. PubMed ID: 8143011 [TBL] [Abstract][Full Text] [Related]
31. The measles-mumps-rubella vaccination program in Finland. Redd SC; Wharton M; Hadler SC; Orenstein WA N Engl J Med; 1995 Apr; 332(16):1102-3. PubMed ID: 7898540 [No Abstract] [Full Text] [Related]
32. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children. Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response. Nakayama T; Urano T; Osano M; Nakagawa M; Maehara N; Sasaki K; Yamamura AM; Makino S Microbiol Immunol; 1990; 34(6):497-508. PubMed ID: 2120551 [TBL] [Abstract][Full Text] [Related]
34. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection. Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672 [TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041 [TBL] [Abstract][Full Text] [Related]
36. A field with a liver measles-mumps-rubella vaccine. Walters VW; Miller SA; Jackson JE; Kenny MT Clin Pediatr (Phila); 1975 Oct; 14(10):928-33. PubMed ID: 1100294 [TBL] [Abstract][Full Text] [Related]
37. Determination of measles, mumps, and rubella immunization status using oral fluid samples. Thieme T; Piacentini S; Davidson S; Steingart K JAMA; 1994 Jul; 272(3):219-21. PubMed ID: 8022041 [TBL] [Abstract][Full Text] [Related]
38. Prevalence of hepatitis B markers and measles, mumps, and rubella antibodies among Jewish refugees from the former Soviet Union. Hurie MB; Gennis MA; Hernandez LV; Dindzans VJ; Davis JP JAMA; 1995 Mar 22-29; 273(12):954-6. PubMed ID: 7884955 [TBL] [Abstract][Full Text] [Related]
39. Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Swartz TA; Klingberg W; Klingberg MA Infection; 1974; 2(3):115-7. PubMed ID: 4606362 [No Abstract] [Full Text] [Related]
40. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]